Dermata Therapeutics, Inc. DRMA
Set alert
0.78 USD -0.06 -6.65%
At close · Oct 30
0.79 +0.01 +1.92%
After hours · Oct 30, 7:59 PM ET
0.7637 Day range 0.829
0.663 52-week range 3.43
- YTD
- -66.59%
- 1 year
- -77.41%
- Open
- 0.799
- Prev close
- 0.8302
- Mkt cap
- 3.84M
- Vol
- 62.20K
- Avg vol
- 3.44M
- EPS
- -4.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7637
- High
- 0.829
- Forward P/E
- -0.32
- Beta
- 0.79
- Short ratio
- 0.52
- Inst. own
- 0.66%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.27
- 200-d avg
- 2.84
- 1y target
- 6.00
2Y chart
Events in this range
- Nov 13, 2024Earnings: -2.04; estimate 0; surprise —%
- Aug 1, 2025Split: 1 for 10
Signals (98)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 3 days ago |
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bullish | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 22, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 4 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| MACD: Sell Signal | May 11, 2026 | 5 months ago |
| SMA: Bearish | May 8, 2026 | 5 months ago |
| SMA: Bullish | May 7, 2026 | 5 months ago |
| SMA: Bearish | May 6, 2026 | 5 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 28, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 16, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 4, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Jan 30, 2026 | 9 months ago |
| SMA: Bullish | Jan 26, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 31, 2025 | 10 months ago |
| RSI: Oversold | Dec 23, 2025 | 10 months ago |
| RSI: Oversold | Dec 19, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 16, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 24, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 18, 2025 | 11 months ago |
| RSI: Oversold | Nov 17, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 12, 2025 | 11 months ago |
| RSI: Oversold | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 28, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 24, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 6, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 24, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 10, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 9, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 2, 2025 | 1 year ago |
| SMA: Bearish | Aug 6, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 6, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 5, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 30, 2025 | 1 year ago |
| SMA: Bullish | Jul 29, 2025 | 1 year ago |
| SMA: Bearish | Jul 24, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 2, 2025 | 1 year ago |
| RSI: Oversold | Jun 30, 2025 | 1 year ago |
| RSI: Oversold | Jun 25, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 6, 2025 | 1 year ago |
| MACD: Sell Signal | May 28, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 25, 2025 | 1 year ago |
| RSI: Oversold | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Apr 9, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 28, 2025 | 1 year ago |
| SMA: Bullish | Mar 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 20, 2025 | 1 year ago |
| SMA: Bullish | Mar 19, 2025 | 1 year ago |
| SMA: Bearish | Mar 11, 2025 | 1 year ago |
| SMA: Bullish | Mar 10, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 7, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 28, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 21, 2025 | 1 year ago |
| SMA: Bearish | Feb 19, 2025 | 1 year ago |
| SMA: Bullish | Feb 18, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 18, 2025 | 1 year ago |
| SMA: Bearish | Feb 6, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 6, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 5, 2025 | 1 year ago |
| SMA: Bullish | Feb 4, 2025 | 1 year ago |
| SMA: Bearish | Jan 29, 2025 | 1 year ago |
| SMA: Bullish | Jan 28, 2025 | 1 year ago |
| SMA: Bearish | Jan 22, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
Key statistics
- Market cap
- 2.51M
- Enterprise value
- -3.38M
- Trailing P/E
- 0.00
- Forward P/E
- -0.32
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.05
- EPS (TTM)
- -13.36
- Beta
- 0.79
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.24M
- Total cash
- 4.95M
- Total debt
- 0
- Return on equity
- -173.01%
- Shares outstanding
- 2.04M
- Short % of float
- 6.28%
- 50-day average
- 1.27
- 200-day average
- 2.84
Analyst view
Consensus: none
Price target (mean) 6.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
DRMA Revenue — quarterly 0
DRMA Net income — quarterly -2.97M
DRMA EPS — quarterly -0.74
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -2.04 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | -4.18 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -7.05 | — | — |
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | -3.15 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -8.10 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -9.45 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 2024 | Maxim Group | main | Buy | Buy |
| Mar 23, 2023 | Maxim Group | main | — | Buy |
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dermatarx.com
News
- Dermata Therapeutics Enrolls First Participant In Its Clinical Trial Evaluating Tome Clearing Treatment For Acne; Expects To Launch This Second Commercial Product In H1 2027
- Why Is Dermata Therapeutics Stock Gaining Thursday?
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
- Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
- Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
- Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on DRMA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.14% | 2,892 | 3.56K | Sep 29, 2024 |
| Wells Fargo & Company | 0.10% | 2,045 | 2.52K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 1,497 | 1.84K | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 10 | 12 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.32% | 6,582 | 8.10K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 1,826 | 2.25K | Oct 30, 2024 |